NM
RCKT icon

Newtyn Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Newtyn Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Buy
4,000,000
+834,100
+26% +$2.77M 1.71% 21
2026
Q1 		$11.3M Buy
3,165,900
+515,900
+19% +$2.05M 1.21% 19
2025
Q4 		$9.3M Buy
2,650,000
+147,137
+6% +$504K 0.98% 21
2025
Q3 		$8.16M Buy
2,502,863
+502,863
+25% +$1.58M 1% 27
2025
Q2 		$4.9M Buy
+2,000,000
New +$10.1M 0.74% 27

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Newtyn Management's RCKT Position: Q2 2026 in Review

Newtyn Management increased its Rocket Pharmaceuticals (RCKT) stake by 26% in Q2 2026, buying an estimated $2.77M and bringing the position to 4,000,000 shares worth $13.7M. The position accounts for 1.71% of the portfolio, ranked #21.

Newtyn Management first reported a position in RCKT in Q2 2025 and has held it in 5 quarters since. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Newtyn Management held 4,000,000 shares of Rocket Pharmaceuticals worth $13.7M as of Q2 2026.
  • Newtyn Management bought 834,100 Rocket Pharmaceuticals shares in Q2 2026, an estimated $2.77M.
  • Rocket Pharmaceuticals made up 1.71% of Newtyn Management's portfolio in Q2 2026, its #21 holding.
  • Newtyn Management first reported a position in Rocket Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Newtyn Management's 13F filing for Q2 2026, filed 14 Aug 2026.